DNA250117C1000
- 0.01
- 0.000.00%
Ginkgo Bioworks Newsroom
All You Need to Know About Ginkgo Bioworks (DNA) Rating Upgrade to Buy
Ginkgo Bioworks, Carnegie Mellon University Secure $9.4 Mln To Build Devices For Disease Treatment
Express News | Ginkgo Bioworks Awarded $9.4 Million in Partnership With Carnegie Mellon University to Develop Implantable Cell-Based Bioelectronic Devices for Disease Treatment Under Arpa-H's React Program
Ginkgo Bioworks Awarded $9.4 Million in Partnership With Carnegie Mellon University to Develop Implantable Cell-Based Bioelectronic Devices for Disease Treatment Under ARPA-H's REACT Program
Ginkgo Bioworks Falls -8.3%
Ferment Launches $20M Studio Fund to Accelerate Biotech Solutions Across Vital Industries
Morgan Stanley Maintains Ginkgo Bioworks(DNA.US) With Hold Rating, Maintains Target Price $10
BTIG Maintains Ginkgo Bioworks(DNA.US) With Sell Rating, Cuts Target Price to $6
Ginkgo Bioworks Price Target Lowered to $6 From $7 at BTIG
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Ginkgo Bioworks's Restructuring Starting to Bear Fruit, Says TD Cowen
TD Cowen Maintains Ginkgo Bioworks(DNA.US) With Buy Rating, Maintains Target Price $10
Positive Outlook for Ginkgo Bioworks: Strategic Developments and Financial Strength Bolster Buy Rating
Ginkgo Bioworks Reports Q3 Growth and Strategic Deals
Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2024 Earnings Call Transcript Summary
Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2024 Earnings Call Transcript
10-Q: Q3 2024 Earnings Report
8-K: Ginkgo Bioworks Reports Third Quarter 2024 Financial Results
Ginkgo Bioworks Raises FY24 Revenue From $170M-$190M To $215M-$235M Vs $185.52M Est.
Ginkgo Bioworks Holdings Q3 EPS $(1.08) Beats $(2.71) Estimate, Sales $89.05M Beat $45.00M Estimate